The agency has granted the drug and CDx priority review, which Myriad expects to conclude during its fiscal third-quarter ending March 31, 2018.
The index gained 1 percent, outperforming the Nasdaq Biotechnology Index, but underperforming the Dow, which gained 2 percent.
The investment firm noted that Myriad is still trying to stabilize its hereditary cancer testing business while diversifying its portfolio to drive future growth.
Smaller labs, hospital outreach labs, and labs servicing high numbers of elderly are thought to face the highest risks.
The biggest losers following the release of the preliminary PAMA rates may be Quest and LabCorp, analysts said today.
Two speakers at the National Society of Genetic Counselors annual meeting discussed how often genetic variants are reclassified and how that affects patients.
The Index gained 4 percent, outperforming the Dow and the Nasdaq, but underperformed the Nasdaq Biotechnology Index, which rose 5 percent.
Once these coverage decisions are fully implemented, 90 percent of breast cancer patients will have coverage for EndoPredict, Myriad estimated.
During an earnings call, company executives discussed plans to grow reimbursement of new tests, stabilize pricing, and save costs through a number of projects.
The increase in overall fourth quarter sales was due to contributions from new products in the company's portfolio.
Using DNA to sketch crime victims might not be a great idea, the NYTimes says.
Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.
Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.
In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.